AzTrials
AzTrials

Major Depressive DisorderNCT03998748

Electrophysiological Correlates of Cognition in Depression

A study of Major Depressive Disorder, run by Mclean Hospital at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Biogenetic messages about the etiology of mental illness (e.g., the "chemical imbalance theory" of depression) are increasing but the impact that these have on decision-making and motivation is not yet clear. Read more about this study

Who is it for?
Ages 18 to 45 years
Conditions the study is for
Major Depressive Disorder
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
80 participants
Where
1 siteUnited States
Study dates
8 Oct 2019to 1 Aug 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Age 18-45
  • Written informed consent
  • BDI-II score greater than or equal to 14 (Beck et al.,1996)
  • Right-handed (Chapman \& Chapman,1987)
  • Normal or corrected-to-normal vision and hearing
  • Fluency in written and spoken English
  • Absence of any psychotropic medications for at least 2 weeks
  • Absence of any psychotherapy for at least 2 weeks

Who cannot join

  • Participants with suicidal ideation where study participation is deemed unsafe by the study clinician
  • Serious or unstable medical illness (cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic, autoimmune disease, etc.)
  • History of seizures or seizure disorder
  • Patients with psychotic features
  • Current use of other psychotropic drugs
  • Current use of psychotherapy
Show all 19Show fewer
  • Clinical or laboratory evidence of hypothyroidism, hyperthyroidism, or other thyroid disorder that is not controlled by medication
  • Patients with a lifetime history of electroconvulsive therapy (ECT)
  • Evidence of sickle cell anemia, Raynaud's disease, ulcerative skin diseases, and hemophilia
  • Evidence of significant inconsistencies in self-report measures
  • History or current diagnosis of dementia
  • Illness receiving acute treatment at time of EEG session (e.g., taking antibiotics)
  • Infections illness (either transient or chronic, such as Lyme disease) at time of EEG session
  • Hairstyles that prevent application of the EEG cap (e.g., braids, dread locks, corn rows, recently dyed hair)
  • History of any psychiatric genotyping
  • History of regular marijuana use (5-7x) per week before age 15
  • History of significant head injury of concussion with loss of consciousness of two minutes or more, or head injury with lingering functional/psychological impact
  • Any alcohol-induced blackouts within the past year
  • Any current drug use as assessed by a urine drug test (covering cocaine, cannabinoids, opiates, amphetamines, methamphetamines, phencyclidine, MDMA, benzodiazepines, methadone, oxycodone, tricyclic antidepressants, and barbiturates)

Trial locations and contacts

1 site in 1 country.

United States1 site
  • McLean Hospital

    Belmont, Massachusetts, 02478

Other trials in United States

About this study

Biogenetic messages about the etiology of mental illness (e.g., the "chemical imbalance theory" of depression) are increasing but the impact that these have on decision-making and motivation is not yet clear. This study will evaluate the impact of biogenetic feedback on cognitive control and default-mode network functioning, as well as motivation for different psychiatric treatment modalities. Participants with major depressive disorder (MDD) will be instructed that they are being tested for genetic susceptibility to depression and will be randomized to receive feedback that they either do or do not have a genetic predisposition to depression. Before and after receiving this feedback, brain activity will be assessed using high-density electroencephalogram (EEG). The investigators hypothesize that those exposed to the genetic feedback condition will evidence heightened ruminative default mode network activity and perceive medications to be more effective than psychotherapy.

Read the detailed description
  1. Background and Significance Depictions of psychiatric illnesses as stemming largely from biological and genetic vulnerabilities have increased substantially in recent years (Deacon, 2013; Lebowitz \& Appelbaum, 2019; Schomerus et al., 2012). These messages are disseminated by physicians, pharmaceutical companies, anti-stigma campaigns, researchers, and the popular media alike. Although at first blush messages emphasizing genetic susceptibility may seem helpful in reducing stigma, growing research points to serious unintended consequences (Haslam \& Kvaale, 2015). Specifically, when participants believe their depression is due to biogenetic abnormalities, they expect to suffer for longer periods of time (Kemp, Lickel, \& Deacon, 2014), endorse more depressive symptoms (Lebowitz \& Ahn, 2017), and feel they have less control over their mood (Lebowitz \& Ahn, 2018). Moreover, biogenetic messaging has no impact on stigma (Haslam \& Kvaale, 2015). Despite the accumulating self-reported evidence that biogenetic messaging may be harmful, nothing is known about how such messages impact neural correlates of self-reflection and cognitive control - two key processes thought to subserve adaptive self-regulation that may be disrupted among individuals with major depressive disorder (MDD, Pizzagalli, 2011). This study will fill this knowledge gap by comparing resting and task-related electroencephalography (EEG) between adults with MDD randomly assigned to receive either positive or negative information about their genetic susceptibility to depression. Completion of this project will characterize the neural impacts of widespread messages about the etiology of depression. This study may inform clinical decision making, public policy, and guidelines regarding how mental health is discussed.
  2. Specific Aims:

Aim1: To examine the impact of biogenetic messaging on default-mode network (DMN) Hypothesis 1: The DMN refers to a network of functionally connected brain regions that are most active at rest and during retrospection (Buckner, Andrews-Hanna, \& Schacter, 2008; Raichle, 2015). The DMN has been consistently found to be overactive in the context of depressive disorders (Pizzagalli, 2011), especially in the context of elevated rumination. Capitalizing on approaches to probe DMN functionality using source-localized EEG activity implemented in the mentor's lab (Whitton et al., 2018) the investigators expect that the DMN will be increased following the positive (vulnerable) genetic feedback manipulation. This would indicate that biogenetic messaging increases potentially maladaptive rumination.

Aim 2: To examine the impact of biogenetic messaging on cognitive control Hypothesis 2: Cognitive control refers to a suite of functions that allow humans to monitor, detect, and respond to conflicting information and mistakes, and to mobilize internal resources to resolve such occurrences from happening in the future (Braver, 2012; Miller \& Cohen, 2001). One commonly studied facet of cognitive control is error monitoring, which refers to the ability to detect and respond to mistakes. The error-related negativity (ERN) is elicited 0-100ms following an error and the error positivity (Pe) is elicited 200-400ms post-error (Gehring, Liu, Orr, \& Carp, 2012). Post-error behavioral adjustments include post-error slowing and post-error improvement in accuracy. Previous research suggests that depressive symptoms correlate with ERN and Pe amplitudes (Compton et al., 2008; Holmes \& Pizzagalli, 2008; Olvet, Klein, \& Hajcak, 2010; Schroder, Moran, Infantolino, \& Moser, 2013). Induction of genetic messaging about intelligence increased the Pe amplitude but also reduced the correlation between Pe and post-error performance (Schroder, Moran, Donnellan, \& Moser, 2014). Accordingly, in the current study, the investigators expect the Pe to be increased and a reduced relationship between Pe and post-error behavior in the vulnerable genetic condition.

Aim 3: To evaluate self-reported motivation for treatment, expectancies, and preferences Hypothesis 3: Previous research has documented a cost in self-reported motivation and future expectancies following receiving biogenetic information about depression (Kemp et al., 2014; Lebowitz \& Ahn, 2017). The investigators expect to replicate these effects in a sample of individuals with MDD. The investigators expect that participants receiving vulnerable genetic feedback will 1) endorse poorer perceived control over their emotions, 2) expect to have depression for a longer period of time, 3) endorse a preference for pharmacotherapy versus psychotherapy and 4) view pharmacotherapy as more effective than psychotherapy.

  1. Description of the Research Design Participants The sample will consist of 80 male and female unmedicated adults with MDD, aged 18-45. Participants will be recruited primarily through Cragslist ads, flyering, and contacting participants who were previously enrolled in studies at the Center for Depression, Anxiety and Stress Research. After passing an initial phone screen, participants will complete the Mini International Neuropsychiatric Interview (MINI; Sheehan et al., 1988). Exclusion criteria for all participants will include failure to meet EEG safety requirements, current drug use, history of alcohol and drug dependence, lifetime history of psychosis and bipolar disorder, and imminent suicidal ideation. After the interview, participants will be asked to complete the Beck Depression Inventory (BDI-II, Beck, Steer, \& Brown, 1996), the Quick Inventory of Depressive Symptoms (QIDS, Rush et al., 2003), the Ruminative Response Style Questionnaire (RRS, Treynor, Gonzalez, \& Nolen-Hoeksema, 2003), the Penn State Worry Questionnaire (PSWQ, Meyer, Miller, Metzger, \& Borkovec, 1990), the Positive And Negative Affective Schedule (PANAS, Clark \& Watson, 1991) and Visual Analogue Mood Scale (VAMS, Aitken, 1969).

Baseline EEG Assessment After participants are deemed eligible, they will complete the baseline EEG assessment. Participants will be fitted with a 96-channel EEG cap. The baseline EEG assessment consists of two tasks. First, resting EEG data will be collected (8 min) in which participants will sit calmly with their eyes open or closed (randomly alternated in one-minute intervals). The resting EEG allows for collection of DMN. Second, participants will perform a flanker task (20 min). The flanker task is a well-validated task in which participants view five horizontal arrows on the computer screen and respond as quickly and as accurately to the central (target) stimulus using a response pad. Participants will complete 30 practice trials to titrate task difficulty in the main blocks, and 350 test trials. The ERN, Pe, behavioral adjustments and VAMS will be recorded from this task.

Saliva Sample and Genetic "Testing" Following completion of the flanker task, participants will be informed they will be taking a saliva sample to determine their genetic susceptibility to depression. Using a previously validated procedure (Lebowitz \& Ahn, 2017, 2018), participants will be provided with a "saliva testing kit", which consists of a plastic box containing a glucose test strip (which participants are led to believe gauges salivary levels of 5-Hydroxyindoleacetic acid (5-HIAA) as part of a genetic susceptibility test) and a small amount of mouthwash (containing glucose) in a plastic container. Participants will be provided with instructions on the computer screen for how to complete the saliva testing themselves. Participants will rinse their mouths with mouthwash for seven seconds, spit the mouthwash into the box, and insert the test strip under their tongues for 10 seconds, and then wait for 30 seconds. The test strip will turn brown as the strip is sensitive to glucose. Participants will be given a computer prompt to indicate which color their test strip turned (brown or pink) and will be randomly assigned to receive computer feedback indicating that a brown test strip means they 1) have a genetic vulnerability to depression or 2) do not have such a vulnerability. The feedback consists of one paragraph describing 5-HIAA and its implications for depression based on past research. The research assistant (RA) will be blind to condition assignment.

Post-Manipulation EEG and Self-reported Assessment Immediately following the genetic test manipulation, participants will complete the PANAS to assess state affects and then repeat the resting EEG recording and flanker task. They will then complete a battery of self-report measures to gauge their hypothetical mental health treatment preferences and expectancies, and perceived willingness to engage in treatment in the future. They will also complete the VAMS, the Implicit Theories Questionnaire (Schroder, Dawood, Yalch, Donnellan, \& Moser, 2015), the Negative Mood Regulation Scale (Catanzaro \& Mearns, 1990), the Perceptions of Depression Scale(Deacon \& Baird, 2009), and the Prognostic Pessimism Scale (Lebowitz, Ahn, \& Nolen-Hoeksema, 2013). Participants will also complete a manipulation check to assess perceived credibility of the genetic testing.

Debriefing Procedure At the end of the session, all participants will be thoroughly debriefed. Following previously published procedures (Lebowitz \& Ahn, 2017), debriefing will entail the Co-I - who has a PhD in clinical psychology - explaining that no genetic testing actually took place. The Co-I will explain that the mouthwash consisted of glucose and that when exposed to glucose, the test strip turns brown. Participants will be shown both feedback screens (susceptible and non-susceptible feedback). The concept of randomized assignment will be discussed. Participants will be encouraged to ask questions during this period. Finally, participants will complete a short quiz consisting of items that ask whether or not genetic testing took place. Participants will be required to respond accurately; if they do not respond accurately after debriefing, the Co-I will again emphasize that no genetic testing took place until full comprehension is achieved.

Being tested
Sham Genetic Feedback
Medical subject headings
Depressive Disorder, Major

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Sham Genetic FeedbackOther

    Participants will be told either that they have or do not have a genetic predisposition to developing depression.

Study groups in NCT03998748
Study groupRoleWhat they receive
ExperimentalExperimentalThis group of participants will receive the feedback that they have a genetic vulnerability to depression.
Receives: Other: Sham Genetic Feedback
ControlActive comparatorThis group of participants will receive the feedback that they do not have a genetic vulnerability to depression.
Receives: Other: Sham Genetic Feedback

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Default Mode Network Connectivity

    Resting-state EEG

    Measured: Through study completion (approximately at hour 4 of study)

  2. Error Positivity (Pe)

    Elicited between 200-500ms following an error

    Measured: Through study completion (approximately at hour 4 of study)

Secondary outcomes (1)
  1. Treatment Credibility and Expectancy Questionnaire

    Perceived credibility of medications and psychotherapy

    Measured: Through study completion (approximately at hour 4 of study)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Jun 2019
  2. Study start8 Oct 2019
  3. Primary completion1 Aug 2021
  4. Study completion1 Aug 2022

Why it stopped: Pandemic

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Factorial
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
80 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03998748
Sponsor's protocol ID
2019P001081
Status last verified
Jan 2023
First submitted
21 Jun 2019
Last updated
19 Jan 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Deacon BJ. The biomedical model of mental disorder: a critical analysis of its validity, utility, and effects on psychotherapy research. Clin Psychol Rev. 2013 Nov;33(7):846-61. doi: 10.1016/j.cpr.2012.09.007. Epub 2013 Apr 8.

    PubMed 23664634
  • Haslam, N., & Kvaale, E. P. (2015). Biogenetic Explanations of Mental Disorder: The Mixed-Blessings Model. Current Directions in Psychological Science, 24(5), 399-404.

  • Lebowitz MS, Appelbaum PS. Biomedical Explanations of Psychopathology and Their Implications for Attitudes and Beliefs About Mental Disorders. Annu Rev Clin Psychol. 2019 May 7;15:555-577. doi: 10.1146/annurev-clinpsy-050718-095416. Epub 2018 Nov 16.

    PubMed 30444641
  • Schomerus G, Schwahn C, Holzinger A, Corrigan PW, Grabe HJ, Carta MG, Angermeyer MC. Evolution of public attitudes about mental illness: a systematic review and meta-analysis. Acta Psychiatr Scand. 2012 Jun;125(6):440-52. doi: 10.1111/j.1600-0447.2012.01826.x. Epub 2012 Jan 13.

    PubMed 22242976
  • Beck, A., Steer, R., & Brown, G. (1996). Beck Depression Inventory-II. San Antonio.

  • Aitken RC. Measurement of feelings using visual analogue scales. Proc R Soc Med. 1969 Oct;62(10):989-93. doi: 10.1177/003591576906201005. No abstract available.

    PubMed 4899510
  • Braver TS. The variable nature of cognitive control: a dual mechanisms framework. Trends Cogn Sci. 2012 Feb;16(2):106-13. doi: 10.1016/j.tics.2011.12.010. Epub 2012 Jan 12.

    PubMed 22245618
  • Buckner RL, Andrews-Hanna JR, Schacter DL. The brain's default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci. 2008 Mar;1124:1-38. doi: 10.1196/annals.1440.011.

    PubMed 18400922
  • Catanzaro SJ, Mearns J. Measuring generalized expectancies for negative mood regulation: initial scale development and implications. J Pers Assess. 1990 Summer;54(3-4):546-63. doi: 10.1080/00223891.1990.9674019.

    PubMed 2348341
  • Clark LA, Watson D. Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications. J Abnorm Psychol. 1991 Aug;100(3):316-36. doi: 10.1037//0021-843x.100.3.316.

    PubMed 1918611
  • Compton RJ, Lin M, Vargas G, Carp J, Fineman SL, Quandt LC. Error detection and posterror behavior in depressed undergraduates. Emotion. 2008 Feb;8(1):58-67. doi: 10.1037/1528-3542.8.1.58.

    PubMed 18266516
  • Deacon, B. J., & Baird, G. L. (2009). The Chemical Imbalance Explanation of Depression: Reducing Blame at What Cost? Journal of Social and Clinical Psychology, 28(4), 415-435.

  • Gehring, W., Liu. Y., Orr. J., & Carp. J. (2012). The Error-related negativity (ERN/Ne). In S. J. Luck & E. Kappenman (Eds.), Oxford handbook of event-related potential components (pp. 231-291). New York: Oxford University Press.

  • Holmes AJ, Pizzagalli DA. Spatiotemporal dynamics of error processing dysfunctions in major depressive disorder. Arch Gen Psychiatry. 2008 Feb;65(2):179-88. doi: 10.1001/archgenpsychiatry.2007.19.

    PubMed 18250256
  • Kemp JJ, Lickel JJ, Deacon BJ. Effects of a chemical imbalance causal explanation on individuals' perceptions of their depressive symptoms. Behav Res Ther. 2014 May;56:47-52. doi: 10.1016/j.brat.2014.02.009. Epub 2014 Mar 6.

    PubMed 24657311

Questions about this trial

What is this clinical trial studying?

A study of Major Depressive Disorder, run by Mclean Hospital at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 19 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Pandemic). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Default Mode Network Connectivity (time frame: Through study completion (approximately at hour 4 of study)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03998748, which also lists 31 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jan 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in